{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"ADA ever-positive was defined as at least one positive ADA result at any time point.","groups":[{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 sub-cutaneous \\[SC\\] administered at weekly intervals, followed by 5 intra tumoral \\[IT\\] administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W. Phase 2 was not planned.","id":"OG000","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg + Avelumab"},{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 SC administered at weekly intervals, followed by 5 IT administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W all cohorts plus utomilumab 100 mg administered IV Q4W. Phase 2 was not planned.","id":"OG001","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg Then Avelumab + Utomilumab 100 mg"},{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 SC administered at weekly intervals, followed by 5 IT administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W all cohorts plus PF-04518600 at 0.3 mg/kg administered IV Q2W. Phase 2 was not planned.","id":"OG002","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg Then Avelumab + PF-04518600 0.3 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis population was subset of safety analysis set (participants who received at least one dose of study drug) and included participants who had at least one ADA sample collected for avelumab. There was no evaluable participant for PF-04518600 ADA for arms \"Phase 1b SCCHN CMP-001 10 mg + Avelumab\" and \"Phase 1b SCCHN CMP-001 10 mg then Avelumab + PF-04518600 0.3 mg/kg.\" Here, \"Number of participants analyzed'' signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Cycle 1, 2, 4, 6, and 10","title":"Number of Participants With Positive ADA Levels Against Utomilumab For Combination F","type":"SECONDARY","unitOfMeasure":"Participants"}